LGT Fund Management Co Ltd. Sells 20,500 Shares of Pfizer Inc. $PFE

Key Points

• LGT Fund Management Co Ltd. reduced its stake in Pfizer by 47.1%, selling 20,500 shares and leaving them with 23,050 shares valued at $559,000.
• Multiple institutional investors have altered their positions in Pfizer, with Bessemer Group Inc. increasing its holdings by 11.1% and Bourne Lent Asset Management Inc. boosting its position by 90.8%.
• Wall Street analysts have mixed opinions on Pfizer, with an average rating of "Hold" and a price target of $28.41.

LGT Fund Management Co Ltd. lowered its position in Pfizer Inc. (NYSE:PFE - Free Report) by 47.1% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,050 shares of the biopharmaceutical company's stock after selling 20,500 shares during the period. LGT Fund Management Co Ltd.'s holdings in Pfizer were worth $559,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Bessemer Group Inc. raised its position in shares of Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK increased its position in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer during the 1st quarter valued at approximately $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer during the 1st quarter valued at approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. increased its position in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on PFE shares. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Bank of America raised their price objective on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Finally, UBS Group reaffirmed a "neutral" rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $28.41.

Pfizer Stock Up 1.1%

Pfizer stock opened at $27.37 on Friday. The firm has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The stock has a fifty day simple moving average of $24.67 and a two-hundred day simple moving average of $24.14. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.